IFN-DLI for Relapsed Acute Leukemia After Allo-SCT

Leukemia Clinical Trial

Official title:

A Pilot Study to Determine the Feasibility of Conventional Induction Chemotherapy Followed by G-CSF Mobilized Donor Leukocyte Infusion (DLI) and IFN-α (IFN-DLI) for Relapsed Acute Leukemia After Allogeneic Stem Cell Transplantation.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02331706
• Other study ID #: UPCC 09414
• Status: Completed
• Phase: Early Phase 1
• Start date: December 2014
• Est. completion date: November 11, 2017

Study information

• Verified date: April 2020
• Source: Abramson Cancer Center of the University of Pennsylvania
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This trial is designed to determine the feasibility of conventional induction chemotherapy, IFNand G-CSF mobilized DLI (IFN-DLI) in subjects with relapsed AML and ALL after allo-SCT.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 16
• Est. completion date: November 11, 2017
• Est. primary completion date: November 11, 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

DLI Recipient

• Relapsed AML or ALL = 60 days after allogeneic SCT.

• Evidence of residual donor chimerism on most recent analysis (within 4 weeks of enrollment).

• Age = 18 years of age,

• Karnofsky performance status = 60%.

• Absence of active GVHD and off immunosuppression. Subjects on tapering prednisone will be eligible if their dose is 0.25 mg/kg or less and being actively tapered. We suggest a 28 day waiting period off of immunosuppression but some subjects with rapidly progressive disease may need to be treated before 30 days and will still be eligible.

• Adequate organ function: Cr = 2 mg/dL; ALT/AST < 3x ULN, direct bili <3x ULN.

• Matched sibling or un-related donor (A, B, C, and DR) available to undergo leukopheresis.

• Subjects must be able to sign consent and be willing and able to comply with scheduled visits, treatment plan and laboratory testing.

• Willing to provide blood samples for research purposes.

• Willing to adhere to medically accepted form of birth control to prevent pregnancy (includes: complete abstention from intercourse, condoms, diaphragms, cervical cap, intra-uterine device, history of surgical sterility - tubal ligation or vasectomy in patient or partner, or oral contraceptive).

DLI Donor

1. HLA identical to recipient subject.

2. Considered medically eligible for leukopheresis procedure by independent donor physician (University of Pennsylvania physician who is not the recipient's primary transplant physician for related donors; physician designated by National Marrow Donor Program for unrelated donors).

3. Considered medically eligible to receive G-CSF (filgrastim) by independent donor physician.

Exclusion Criteria

Recipient

• Prior cell therapy for relapse within the past 90 days.

• Requirement for active immunosuppression to treat GVHD.

• Pregnant or lactating women. The safety of this therapy on unborn children and effects on breast milk are not known.

• Uncontrolled active infection

• Any uncontrolled active medical disorder that would preclude participation as outlined.

Donor

• Unable to participate in a leukopheresis procedure or receive G-CSF (filgrastim).

Related Conditions & MeSH terms

• Leukemia

Intervention

Drug:
• Interferon alpha-2B (IFN-a) 3 million units (MU) subcutaneous daily

Locations

Country	Name	City	State
United States	Abramson Cancer Center of the University of Pennsylvania	Philadelphia	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
Abramson Cancer Center of the University of Pennsylvania

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of Adverse Events		2 years
Secondary	overall survival		2 years
Secondary	disease-free survival		2 years